Levetiracetam in Treatment of Epilepsy, Own  Experience of Application in Adult Patients

Торопина, Г.

doi:10.21518/2079-701x-2017-10-60-64

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На сегодняшний день механизм действия леветирацетама остается до конца не выясненным и, по-видимому, отличается от известных механизмов влияния на тормозную и возбуждающую нейротрансмиссию. Предположительные механизмы действия леветирацетама, с одной стороны, могут быть направлены на противодействие патологической нейрональной синхронизации, лежащей в основе эпилептогенеза, с другой -могут определять его нейропротективные свойства [5].…”

unclassified

“…Показано, что отдельным преимуществом препарата эпитерра лонг (леветирацетам) является его пролонгированная форма [5,6]. Биодоступность леветирацетама в лекарственной форме таблеток пролонгированного действия схожа с биодоступностью леветирацетама в лекарственной форме таблеток с немедленным высвобождением.…”

unclassified

See 1 more Smart Citation

Indication of antiepileptic drugs to patients with epilepsy: results of the survey of neurologists

Бурд

Лебедева

Миронов

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Valproic acid was the most frequently used drug followed by levetiracetam and carbamazepine, which reflected the overall picture of PEP indication in patients with epilepsy in the Russian population. Levetiracetam occupies a leading position as the starting drug for treatment of epilepsy; most often prescribed to women, patients with generalized seizures and idiopathic epilepsy. It is the drug of choice as adjuvant remedies for Duo therapy.

show abstract

unclassified

Indication of antiepileptic drugs to patients with epilepsy: results of the survey of neurologists

Бурд

Лебедева

Миронов

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

show abstract

Efficacy assessment of levetiracetam monotherapy in newly-diagnosed epilepsy in adults using epileptiform activity index

Карлов

Кожокару

Власов

et al. 2020

Èpilepsiâ paroksizmalʹnye sostoâ.

View full text Add to dashboard Cite

Abstract. Levetiracetam (LEV) is one of the most commonly prescribed antiepileptic drugs (AED). However, there were no studies on its efficacy and safety in terms of the correlation with epileptiform activity index (EAI) performed among the Russian population.Aim. To evaluate the efficacy and tolerability of LEV monotherapy in patients with newly-diagnosed epilepsy using epileptiform activity index (EAI) assessment.Materials and methods. The study included 107 patients (46 (43.0%) male and 61 (57.0%) female) with focal epilepsy (FE) (39.3%; n=42) or idiopathic generalized epilepsy (IGE) (60.7%; n=65). At each visit, video-electroencephalographic (video-EEG) monitoring was performed (baseline and in 1, 3, 6, and 12 months of the therapy). Therapeutic drug monitoring was performed at dose titration in 1 month of the therapy or in case of therapy correction. Treatment efficacy was assessed using the criteria of seizure absence (medically induced remission), seizure rate decrease by >50% (responders), seizure rate decrease by <50% – insufficient efficacy, a composite index of efficacy/tolerability (retention on treatment), and seizure rate increase compared to baseline and/or development of a new type of seizures (aggravation). Adverse events (AE) were assessed using the scale for side effects in AED treatment (SIDAED).Results. Total EAI at baseline was 5.2-fold higher in patients with IGE compared to FE patients (23.4±3.0 and 4.5±0.97, respectively). After 1 month of LEV therapy, EAI decreased to 3.4±1.1 and 1.9±0.4 in patients with IGE and FE, respectively (p<0.01). The decrease continued during the whole follow-up period. Retention on monotherapy was achieved in 82.2% (n=88/107) patients; in 87.6% (n=57/65) patients with IGE and in 73.8% (n=31/42) with FE. The rate of serious AEs during the follow-up period was 8.4% (n=9).Conclusions. LEV is an effective drug of choice for the initial treatment of newly-diagnosed FE and IGE in monotherapy along with a significant decrease in EAI. EAI is an objective measure of LEV treatment efficacy.

show abstract

Levetiracetam in Treatment of Epilepsy, Own Experience of Application in Adult Patients

Cited by 2 publications

References 20 publications

Indication of antiepileptic drugs to patients with epilepsy: results of the survey of neurologists

Indication of antiepileptic drugs to patients with epilepsy: results of the survey of neurologists

Efficacy assessment of levetiracetam monotherapy in newly-diagnosed epilepsy in adults using epileptiform activity index

Contact Info

Product

Resources

About